Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 364

1.

Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.

Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.

J Clin Pharmacol. 2014 Dec;54(12):1362-7. doi: 10.1002/jcph.342.

PMID:
24906029
2.

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.

Gralla RJ, Ahmad F, Blais JD, Chiodo J 3rd, Zhou W, Glaser LA, Czerwiec FS.

Cancer Med. 2017 Apr;6(4):723-729. doi: 10.1002/cam4.805. Epub 2017 Mar 2.

3.

[The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].

Li L, Bai H, Zhu WL; Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Oct;39(10):936-40. Chinese.

PMID:
22321279
4.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

6.

Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.

Salahudeen AK, Ali N, George M, Lahoti A, Palla S.

Cancer. 2014 Mar 1;120(5):744-51. doi: 10.1002/cncr.28468. Epub 2013 Nov 5.

7.

Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.

Vaghasiya RP, DeVita MV, Michelis MF.

Int Urol Nephrol. 2012 Jun;44(3):865-71. doi: 10.1007/s11255-011-9996-8. Epub 2011 May 24.

PMID:
21607553
8.
9.

Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.

Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G.

Clin J Am Soc Nephrol. 2012 May;7(5):742-7. doi: 10.2215/CJN.06990711. Epub 2012 Mar 8.

10.

Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.

Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM.

Clin Endocrinol (Oxf). 2016 Apr;84(4):620-6. doi: 10.1111/cen.12943. Epub 2015 Nov 3.

PMID:
26385871
11.

[The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].

Rollino C, Balbiano R, Caramello P, Roccatello D.

G Ital Nefrol. 2013 Nov-Dec;30(6). pii: gin/30.6.8. Italian.

PMID:
24402662
12.

Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.

Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, Wang X, Wang JF, Lu W, Li CZ, Mao Y, Wang GQ, Gao YQ, Wang B, Zhang Q, Ge Y, Wong VW.

Ann Hepatol. 2017 Jan-Feb;16(1):123-132. doi: 10.5604/16652681.1226823.

13.

Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion.

Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators.

Eur J Endocrinol. 2011 May;164(5):725-32. doi: 10.1530/EJE-10-1078. Epub 2011 Feb 11.

14.

Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.

Yamashita T, Yoshida M, Yamada H, Asano T, Aoki A, Ikoma A, Kusaka I, Kakei M, Ishikawa SE.

Intern Med. 2014;53(8):845-9. Epub 2014 Apr 15.

15.

Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).

Verbalis JG, Ellison H, Hobart M, Krasa H, Ouyang J, Czerwiec FS; Investigation of the Neurocognitive Impact of Sodium Improvement in Geriatric Hyponatremia: Efficacy and Safety of Tolvaptan (INSIGHT) Investigators.

Am J Kidney Dis. 2016 Jun;67(6):893-901. doi: 10.1053/j.ajkd.2015.12.024. Epub 2016 Feb 11.

PMID:
26874645
16.

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.

De las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R.

Support Care Cancer. 2016 Jan;24(1):499-507. doi: 10.1007/s00520-015-2948-6. Epub 2015 Oct 2.

17.

Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.

Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.

J Hepatol. 2012 Mar;56(3):571-8. doi: 10.1016/j.jhep.2011.08.020. Epub 2011 Oct 23.

PMID:
22027579
18.

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Bordi P, Tiseo M, Buti S, Regolisti G, Ardizzoni A.

Tumori. 2015 Apr 28;101(2):e51-3. doi: 10.5301/tj.5000249.

PMID:
25702667
19.

Tolvaptan.

Plosker GL.

Drugs. 2010 Mar 5;70(4):443-54. doi: 10.2165/11204630-000000000-00000. Review.

PMID:
20205486
20.

Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.

Shanmugam E, Doss CR, George M, Jena A, Rajaram M, Ramaraj B, Anjaneyan K, Kanagesh B.

Indian Heart J. 2016 Apr;68 Suppl 1:S15-21. doi: 10.1016/j.ihj.2015.07.006. Epub 2015 Nov 12.

Supplemental Content

Support Center